Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.42 |
| ▸ | TIPARP | Q7Z3E1 | 3/20 | 0.41 |
| ▸ | KRAS | P01116 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2224823 | 0.90 | GRM5 (0.42) | GRM5HDAC8HDAC6TIPARPHDAC1 | |
| SCHEMBL2225164 | 0.90 | PDK1 (0.44) | CHRM1PDK1PDK2GRM5HDAC8 | |
| SCHEMBL2227438 | 0.89 | GRM5 (0.41) | PARP1PARP2CHRM4PDK1PDK2 | |
| SCHEMBL13838109 | 0.89 | GRM5 (0.46) | PARP1PARP2CHRM1CHRM4PDK1 | |
| SCHEMBL2226665 | 0.86 | HDAC4 (0.52) | PARP1HDAC8HDAC6TIPARP | |
| SCHEMBL2224667 | 0.86 | HDAC6 (0.47) | PDK1PDK2GRM5HDAC8HDAC6 | |
| SCHEMBL2224359 | 0.85 | PDK1 (0.49) | CHRM1PDK1PDK2GRM5HDAC8 | |
| SCHEMBL2226039 | 0.85 | CHRM1 (0.44) | CHRM1GRM5HDAC8HDAC6TIPARP | |
| SCHEMBL2226710 | 0.85 | HDAC6 (0.48) | PARP1CHRM1PDK1PDK2HDAC8 | |
| SCHEMBL2225124 | 0.83 | HDAC6 (0.50) | PARP1HDAC8HDAC6TIPARP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | claimed |
| WO-2013009827-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | claimed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | claimed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2013009827-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
| EP-2523664-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | PARP1 448/4885PARP2 274/4885CHRM1 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.